ArticleTranslational pediatrics2025
Analysis of factors influencing mortality in immunocompetent children with severe adenovirus pneumonia undergoing conventional treatments: a retrospective cohort study.
Article in Translational pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe adenovirus pneumonia (SAP) in immunocompetent children can progress rapidly despite conventional treatment, posing significant clinical challenges. The objective of this study to assess the factors influencing mortality in immunocompetent children with SAP undergoing conventional therapies. Early identification of risk factors for mortality is essential to guide timely intervention and optimize management strategies. Methods: In this study, we conducted a retrospective study of 156 immunocompetent pediatric patients diagnosed with SAP, who were divided into the conventional treatments survivor group and death group, without receiving extracorporeal membrane oxygenation (ECMO). Baseline clinical features, laboratory data, imaging findings, treatments and complications were collected. Patients were followed until discharge or death, with mortality confirmed from medical records. Results: There were 156 children included, with 142 patients in the survivor group and 14 patients in the death group. The mean age was 30.12±28.78 months, with no significant differences in age or sex between the survivor group and the death group (P>0.05). In univariate analysis, significant differences were observed in shortness of breath, tachycardia, low oxygen saturation (SpO Conclusions: These findings emphasize the importance of close monitoring of SpO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.